RESEARCH ARTICLE

Microdialysis combined with liquid chromatography-tandem mass spectrometry for the quantitation of gemifloxacin and its application to a muscle penetration study in healthy and MRSA-infected rats

Rui Zhao, Qing Wang, Xin-Xin Hu, Tong-Ying Nie, Xin-Yi Yang, Cong-Ran Li, Xi Lu, Xiukun Wang, Jian-Dong Jiang, Jing Pang*, Xue-Fu You*

Beijing Key Laboratory of Antimicrobial Agents and Department of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors contributed equally to this work.

Abstract

Pharmacological efficacy is based on the drug concentration in target tissues, which usually cannot be represented by the plasma concentration. The purpose of this study was to compare the pharmacokinetic characteristics of gemifloxacin in plasma and skeletal muscle and evaluate its tissue penetration in both healthy and MRSA (methicillin-resistant Staphylococcus aureus)-infected rats. A microdialysis (MD) combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated to determine free gemifloxacin concentrations in rat plasma and skeletal muscle simultaneously. The in vivo recoveries of MD were 23.21% ± 3.42% for skeletal muscle and 20.62% ± 3.19% for plasma, and were concentration independent. We provided evidence that the method developed here meets FDA requirements. Additionally, this method was successfully applied to the determination of free gemifloxacin in rats. Muscle and blood dialysates were collected after an 18 mg/kg intravenous bolus dose. The mean areas under the concentration-time curves (AUCs) from 0 to 9 h for skeletal muscle and plasma were 3641.50 ± 915.65 h*ng/mL and 7068.32 ± 1964.19 h*ng/mL in MRSA-infected rats and 3774.72 ± 700.36 h*ng/mL and 6927.49 ± 1714.86 h*ng/mL in healthy rats, respectively. There was no significant difference (P>0.05) in gemifloxacin exposure between healthy rats and MRSA-infected rats for plasma or muscle. The low ratio of AUC<sub>0-9</sub> muscle to AUC<sub>0-9</sub> plasma suggested lower drug exposure in skeletal muscle than in plasma for both healthy and MRSA-infected rats. Our study suggested that the administration of gemifloxacin according to drug levels in plasma to treat local infection is unreasonable and might result in an inadequate dose regimen.
Introduction
Antibacterial drug resistance, an urgent global crisis, is seriously threatening public health and social stability. The prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA), a major cause of hospital and community-associated infections, has become the focus of novel antibacterial development. Gemifloxacin (pKa$_1$ = 5.53, pKa$_2$ = 9.53; LogP = 1.7313; molecular weight 389.3809) [1] is a broad-spectrum fluoroquinolone antibacterial with relatively high antimicrobial activity against Gram-positive bacteria. Compared with other quinolones, gemifloxacin shows a better inhibitory effect on topoisomerase IV, a primary target of *Staphylococcus aureus* [2].

The alarming increase in drug resistance is mainly caused by the inappropriate use of antibacterial agents. Pharmacokinetic/pharmacodynamic (PK/PD) studies are a valuable tool to maximize bacteriological cures and minimize drug-resistance mutations in drug development and clinical practice. Quinolones are generally concentration dependent and can rapidly penetrate infected tissue [3–4]. The PK/PD properties of quinolones have been well described, and the ratio of the area under the concentration-time curve to the minimum inhibitory concentration (AUC$_{0-24}$/MIC) has an excellent correlation with clinical efficacy [5]. Pharmacological efficacy is usually related to the free drug concentration in target tissues, but the plasma concentration obtained in pharmacokinetic (PK) studies does not represent the real concentration in the tissue, even taking the protein binding rate into consideration [6]. Therefore, the clinical dosing regimen established based on plasma concentration is questionable. Microdialysis (MD), a technique used to sample protein-free molecules located in a target site by a dialysis membrane, provides the possibility to achieve an appropriate drug concentration in target tissues and is widely utilized in the tissue distribution studies [7–8].

Although gemifloxacin was approved by the U.S. Food and Drug Administration (FDA) only for the treatment of acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia [9], it has also been applied to other local infections by researchers. To date, only one publication by Islinger *et al.* evaluated the free gemifloxacin concentrations in skeletal muscle [10]. However, their study was performed on healthy volunteers rather than infected subjects. In addition, the method the authors employed to obtain the free drug concentrations in plasma according to the plasma protein binding rate may result in inaccurate estimation [11]. Based on this background, we aimed to investigate the muscle distribution of gemifloxacin in infected mammals.

In the present study, *in vivo* MD coupled with LC-MS/MS was established to evaluate the concentrations of unbound gemifloxacin in plasma and skeletal muscle for both MRSA-infected and healthy rats. Thus, the PK profiles of free gemifloxacin in plasma and skeletal muscle can be elucidated, and the tissue penetration ability of gemifloxacin can be clarified.

Materials and methods
Chemicals, reagents and bacterial strain
Gemifloxacin mesylate for injection (purity > 99.7%) was supplied by Livzon Pharmaceutical Group Inc. (Zhuhai, China). Ciprofloxacin (purity > 99%), which served as an internal standard (IS), was purchased from the National Institutes for Food and Drug Control (Beijing, China). The chemical structures of gemifloxacin and ciprofloxacin are shown in Fig 1. Pentobarbital sodium (purity > 99%) was obtained from Sigma-Aldrich Corp. (St Louis, MO, USA). HPLC-grade methanol was purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ultrapure water was obtained from a Millipore water purification system (Bedford, MA, USA). Other chemicals were of analytical grade. Ringer’s solution comprising 145 mM NaCl, 4.02 mM KCl, and 2.24 mM CaCl$_2$ was prepared freshly. MRSA strain ATCC 43300 from the CAMS...
Collection Center of Pathogen Microorganisms (CCPM) was used in this study. Mueller-Hinton broth and agar used for bacterial culture and antimicrobial susceptibility tests were purchased from Becton, Dickinson and Company (Franklin Lakes, NJ, USA).

**Preparation of calibration standards and quality controls**

A stock solution of gemifloxacin was prepared by dissolving gemifloxacin in Ringer’s solution at a concentration of 1 mg/mL. Calibration standards (2, 4, 8, 16, 32, 64, 128 and 256 ng/mL) and quality control (QC) samples (4, 40 and 200 ng/mL) were prepared by subsequent dilutions of stock solution with blank dialysate. The IS stock was prepared at a concentration of 1 mg/mL and subsequently diluted to 10 ng/mL in methanol as the working solution. Both the stock and working solutions were stored at -20˚C. All solutions were kept from light.

**Sample preparation procedure**

Dialysate samples were thawed at room temperature before analysis. The mixture of 20 μL sample or standard, 20 μL IS working solution and 160 μL methanol–water solution (1:1, v/v) was vortexed for 1 min, transferred to a clean autosampler insert, and directly injected into the LC-MS/MS system for determination.

**Instrumentation and analytical conditions**

To collect free gemifloxacin in the interstitial space fluid at the target tissue [12–13], commercially available MD probes (membrane length, 10 mm; membrane diameter, 0.5 mm; membrane materials, polyarylethersulfone; molecular cutoff, 20 kDa; CMA 20, CMA/Microdialysis AB, Stockholm, Sweden) were employed. The MD system was connected to a microinfusion CMA400 syringe pump (flow rate range, 1 nL/min to 1 mL/min; flow rate accuracy, ±1%; flow rate reproducibility, ±0.1%; CMA/Microdialysis AB, Stockholm, Sweden) and a CMA470 refrigerated fraction collector. Each probe was coupled to a gas-tight microliter syringe (500 μl; Hamilton Company, Reno, NV, USA) to provide the perfusion solution. The configuration of the MD system is presented in Fig 2.

LC-MS/MS was performed using a high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan), consisting of an LC-20Adxr pump, a SIL-20Axr autosampler and a CTO-20AC column oven, coupled to an AB SCIEX Qtrap 6500 mass spectrometer (Foster, CA, USA) with an electronic spray ion (ESI) source. Mass spectrometric analysis was acquired in positive ion mode.

Chromatographic separation was achieved using an XTerra MS C18 column (i.d. 50 mm×2.1 mm, 3.5 μm; Waters, Wexford, Ireland) at 35˚C. Mobile phase A and B consisted of
water and methanol, respectively, with both containing 0.2% formic acid. The gradient elution was programmed as follows: 10% B maintained for 1 min, linearly increased to 70% in 1.5 min and maintained for 1 min, decreased to 10% in 0.1 min and equilibrated to the end of analysis. The total run time was 4.5 min at a flow rate of 0.4 mL/min. Analysis was performed by monitoring the transitions of (m/z) $^{+} 390.1 \rightarrow 313.0$ (collision energy 40 eV) and (m/z) $^{+} 332.2 \rightarrow 314.1$ (collision energy 27 eV) for gemifloxacin and IS, respectively, in multiple reactions monitoring (MRM) mode. The MS/MS parameters were set as follows: ion spray voltage, 4.5 KV; source temperature, 550˚C. Data acquisition and processing were performed by Analyst (Version 1.6.2, AB SCIEX Instruments, Foster, CA, USA).

Method validation

The FDA guideline was followed for the validation of this bioanalytical method [14]. Analytical performance parameters, including selectivity, linearity, lowest limit of quantitation, accuracy, precision, and stability of gemifloxacin under various storage conditions were evaluated.

The selectivity of the method was evaluated by comparing the chromatograms of blank dialysates from six individual rats with the corresponding dialysates spiked with gemifloxacin to investigate the interference from endogenous material.

The calibration equation was obtained from a linear least-squares regression of the peak area ratio of gemifloxacin to IS against the corresponding nominal concentration (ranging from 2 to 256 ng/mL) with a weighting index of 1/x. The lowest concentration in the calibration curve with qualified precision (relative standard deviation (R.S.D.) % < 20%) and accuracy (80–120%) was defined as the lower limit of quantitation (LLOQ). The R.S.D. within ±15% for the back calculation from the nominal concentrations was considered acceptable for other levels.

Six replicates of QC standards at three different concentrations (4, 40 and 200 ng/mL) prepared within the same day or on three consecutive days were analyzed for the determination of intra-day and inter-day accuracy and precision. Accuracy was assessed by (mean measured concentration) / (nominal concentration) × 100%, and the precision was expressed in terms of R.S.D.%. The accuracy values should be within 85% to 115%, and the precision values should not exceed 15%.

Six different sources of blank dialysates were used to assess the matrix effect of gemifloxacin at three QC levels. Matrix effects were assessed by comparing the peak area of gemifloxacin added to extracted blank dialysates with that of gemifloxacin added to neat solution. A matrix effect between 80% and 120% is considered ideal. Sample extraction was not involved in the
sample preparation process of this study due to the purity of the dialysates; therefore, extraction recovery was not performed in the method validation.

The analysis of six replicates of QC standards at three concentrations maintained at ambient temperature for 12 h, in storage at −80°C for 2 weeks, after three freeze-thaw cycles, and placed in the autosampler after processing at 4°C for 24 h was applied to the stability evaluation of gemifloxacin.

Relative recoveries of gemifloxacin

To assess the influence of assay methods and drug concentrations on the relative recovery of the probes, both in vitro and in vivo methods were employed in this study. Two different extraction efficiency (EE) and retro-dialysis (RD) methods described by Tasso et al. [15] were applied to the determination of in vitro recovery. EE recovery is defined as the ratio of the concentration in the microdialysate (C_{out}) and the concentration in the solution surrounding the probe. RD recovery can be calculated by the concentration ratio of drug lost during its passage through the probe (C_{in}−C_{out}) and drug entering the probe (C_{in}). For in vivo evaluation, only the RD method was employed. All methods were carried out at 22 ± 2°C.

Assessment of in vitro microdialysis. To assess the recovery dependency on drug concentration and dialysis method, three different concentrations (100, 2000 and 20000 ng/mL) were employed to evaluate the in vitro recoveries of gemifloxacin according to the EE and RD method.

Blank Ringer’s solution was perfused at a flow rate of 2.5 μL/min continuously through the probes (n = 3), which were inserted into different concentrations of gemifloxacin in Ringer’s solutions. Following 1 h of equilibration, dialysate samples were collected every 30 min. The concentrations of gemifloxacin in the solutions and dialysates were measured by the validated LC–MS/MS method to calculate the recovery by the EE method using the following equation:

$$EE\,(\%) = \frac{C_{out}}{C_{sol}} \times 100$$

EE (%) is the relative recovery, C_{out} is the drug concentration of the dialysate, and C_{sol} is the concentration of the solution where the probe was placed in.

In contrast to the EE method described above, the probes (n = 3) placed in the tubes containing blank Ringer’s solution were perfused by gemifloxacin solutions at a constant flow rate of 2.5 μL/min to evaluate the recovery by the RD method. The recoveries were calculated as follows:

$$RD\,(\%) = \frac{(C_{in}−C_{out})}{C_{in}} \times 100$$

RD (%) is the relative recovery, C_{in} is the concentration of the perfusate, and C_{out} is the drug concentration of the dialysate.

Assessment of in vivo microdialysis. To evaluate the probe recoveries in rat skeletal muscle and plasma, probes were inserted through the skeletal muscle and blood vessels [16–17]. To implant the probe in the muscle, an incision was made in the left hind leg skin of an anesthetized rat. Then, a guide cannula was inserted through the skeletal muscle, and the probe was placed inside the guide cannula, which was removed while keeping the probe in place. For the probe implantation in blood, the jugular vein was exposed, an incision was made in the blood vessel, and an MD probe was inserted. The probe was held in place with a tie around the probe shaft and skin.

Gemifloxacin in Ringer’s solutions at different concentrations (100, 2000 and 20000 ng/mL) was pumped through the probes (n = 3) continuously at a flow rate of 2.5 μL/min. After 1 h of equilibration, samples were collected every 30 min for each concentration. The relative
loss of gemifloxacin from the perfusate into the extracellular fluid was used to calculate the in vivo recovery by Eq (2).

**Plasma protein binding studies**

Gemifloxacin plasma protein binding was assessed using Amicon Ultra centrifugal filters (Millipore Corporation; Billerica, MA, USA) with a 30-kDa molecular cutoff. Fortified plasma samples (C\text{plasma}) at concentrations of 10, 1, and 0.05 \( \mu \text{g/mL} \) were incubated at 37 ± 1°C for 30 min, transferred into ultrafiltration tubes, and centrifuged at 2,000 \( \text{g} \) for 40 min to generate ultrafiltrate samples (C\text{ultrafiltrate}). The protein binding rate (%) was calculated as 100 - (100 \times C\text{ultrafiltrate}/C\text{plasma}).

**Animal studies**

The potential of gemifloxacin to penetrate skeletal muscle was investigated in rats. All animal experiments were approved by the Ethics Committee of the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Male Sprague-Dawley rats (200 ± 10 g) were purchased from the Academy of Military Medical Sciences (Beijing, China). Rats were housed under environmentally controlled conditions with a room temperature of 22 ± 2°C, humidity of 55 ± 6%, and 12-h light/12-h dark cycle. Rats received free access to food and water. All rats were euthanized with CO\text{2} after experiments.

**Animal model of thigh infection.** Rats were rendered neutropenic by injecting cyclophosphamide intraperitoneally on day 1 to day 3 at the dose of 35 mg/kg, and the infection was performed on day 4. Twenty microliters of orbital blood was acquired from day 1 until sacrifice, and leukocytes were counted by an inverted microscope AE31 (Motic China Group Co., Ltd., Xiamen, China). The thigh infection was induced by intramuscular injection of 0.1 mL of \textit{S. aureus} ATCC 43300 (approximately 10\(^7\) colony forming units (CFU)/mL) into the left thigh of rats (n = 12). Gemifloxacin (0.2 mL) at a dose of 18 mg/kg or 0.85% NaCl solution was injected into the lateral tail vein 2 h after thigh infection. Rats in both groups were sacrificed 2 h and 26 h after bacterial inoculation, and the thigh muscle was collected, homogenized in 5 mL sterilized saline, and plated to determine the bacterial load. Bacterial counts were recorded as the log\(_{10}\) CFU/thigh.

**Pharmacokinetic study.** After 3 days of acclimatization, rats were randomly divided into two groups (MRSA-infected group, n = 6; healthy control group, n = 6). Animals were anesthetized with pentobarbital sodium (60 mg/kg, i.p.) and immobilized on a dissecting board in the supine position. Anesthesia was confirmed by the absence of reflexes in response to footpad pinching.

MD probes were implanted into plasma and skeletal muscle for sampling as described above. The probes were perfused with Ringer’s solution at a flow rate of 2.5 \( \mu \text{L/min} \) from 1 h before drug administration. A single intravenous dose of 18 mg/kg was administered by the lateral tail vein. The dosage was equivalent to 200 mg i.v. or 320 mg oral (dosage of commercial gemifloxacin tablet) dosing in humans based on the body surface area conversion.

MD samples were collected up to 9 h with the sampling program as follows: every 10 min for the first 1 h; 20 min intervals for the following 3 h; and 30 min intervals for the last 5 h with sampling amounts of 25 \( \mu \text{L} \), 50 \( \mu \text{L} \) and 75 \( \mu \text{L} \), respectively. Dialysate samples were stored at −80°C until analysis. Twenty microliters of dialysates was briefly mixed with 20 \( \mu \text{L} \) IS working solution and 160 \( \mu \text{L} \) methanol–water solution (1:1, v/v), vortexed for 1 min, transferred to a clean autosampler insert, and directly injected into the LC-MS/MS system for determination.

**Tissue uptake study.** Sixteen MRSA-infected rats were randomly divided into four groups of four animals each, corresponding to 0.167, 2, 4, and 9 h postdose for muscle
collection. Gemifloxacin was administered to rats intravenously at a dose of 18 mg/kg. Rats were sacrificed at the sampling time, and muscle samples were removed, rinsed with normal saline solution (0.9%, w/v), wiped dry, and weighed immediately. The tissues were kept frozen at −80˚C until analysis.

**Data analysis**

PK parameters were assessed by Phoenix v. 64 (Pharsight Corp., Mountain View, CA, USA) employing a non-compartmental model. The differences in MD probe recoveries among three concentrations and two methods (RD and EE) were evaluated by one-way ANOVA employing SPSS 16.0. Student’s t-test was conducted on gemifloxacin exposures between healthy rats and MRSA-infected rats. Paired samples t-test was conducted on the PK parameters between muscle and plasma for statistical comparison. A P-value < 0.05 was considered statistically significant.

**Results**

**Method validation of LC-MS/MS analysis**

Selectivity was evaluated by comparing the chromatograms of blank dialysate, blank dialysate spiked with gemifloxacin (40 ng/mL), and dialysate of skeletal muscle or plasma collected 4 h postdose. As shown in Fig 3, no significant endogenous interference was displayed at the retention time of gemifloxacin or ciprofloxacin (IS) in MRM scan mode.

The standard calibration curves showed good linearity with a typical equation of \( y = 0.0307x - 0.049 \) \( (R^2 = 0.9982, \text{Weight: } 1/x) \) over the range of 2−256 ng/mL. All analytical results exhibited less than 15% deviation from the nominal concentrations. The LLOQ was 2 ng/mL with acceptable precision and accuracy.

The results of intra-day and inter-day precision and accuracy are presented in Table 1. R.S. D. (%) values were no more than 14.15% and 11.33% for intra-day and inter-day precision, respectively. The accuracy ranged from 88.25% to 107.73% for all QC levels. The accuracies and precisions for the tested levels were all within the defined acceptable criteria.

As shown in Table 2, the matrix effects were between 91.32% and 102.16%, which suggests the absence of ion suppression or ion enhancement.

The results of the stability study summarized in Table 3 showed that gemifloxacin did not degrade after being placed at room temperature for 12 h or stored at −80˚C for 2 weeks in

![Fig 3. LC–MS/MS chromatograms of gemifloxacin (upper row) and ciprofloxacin (bottom row). (A) Blank dialysate of skeletal muscle; (B) blank skeletal muscle dialysate spiked with gemifloxacin (40 ng/mL); (C) dialysate of skeletal muscle collected 4 h after the administration of gemifloxacin, i.v. (18 mg/kg); (D) blank dialysate of plasma; (E) blank plasma dialysate spiked with gemifloxacin (40 ng/mL); (F) dialysate of plasma collected 4 h postdose.](https://doi.org/10.1371/journal.pone.0217573.g003)
Gemifloxacin was also stable in autosampler at 4°C for 24 h and after undergoing three freeze-thaw cycles.

**In vitro and in vivo recoveries of microdialysis**

The influence of the gemifloxacin concentration and method employed on probe recovery was evaluated. The relative *in vitro* recoveries were 22.15% ± 1.10%, 24.63% ± 2.28% and 23.27% ± 2.01% in the EE method for gemifloxacin concentrations of 100, 2000 and 20000 ng/mL, respectively. The corresponding recoveries measured by the RD method were 23.56% ± 2.77%, 24.28% ± 2.32% and 25.80% ± 2.30%, respectively. There was no significant difference (*P* > 0.05) among the three different drug concentrations or two dialysis methods.

The average *in vivo* recoveries measured by the RD method were 23.21% ± 3.42% for skeletal muscle and 20.62% ± 3.19% for plasma. The *in vivo* recovery values above were employed to back calculate the real gemifloxacin concentrations in rat plasma and skeletal muscle.

**Plasma protein binding**

The *in vitro* protein binding rates of gemifloxacin over three different plasma concentrations were tested. The mean fraction bound to plasma proteins was 74.5% ± 5.7% with no concentration dependence.

**Thigh infection model**

The thigh infection model was successfully established in neutropenic rats. As presented in Fig 4, the bacterial density was 6.07±0.19 log₁₀ CFU/thigh. The bacterial density taken from control animals prior to initiation of dosing was 6.80±0.26 log₁₀ CFU/thigh, which increased to 8.08±0.25 log₁₀ CFU/thigh after 24 h in untreated controls. A single dose of gemifloxacin at 18

| Table 1. Accuracies and precisions of gemifloxacin QC samples. |
| | Nominal concentration (ng/mL) | Intra-day | Inter-day |
| | | Accuracy (%,* n = 6*) | RSD (%,* n = 6*) | Accuracy (%,* n = 18*) | RSD (%,* n = 18*) |
| Day 1 | 4 | 107.73 | 7.75 | 105.49 | 6.38 |
| Day 2 | 103.32 | 7.72 | |
| Day 3 | 105.43 | 3.69 | |
| Day 1 | 40 | 88.25 | 4.43 | 91.22 | 8.58 |
| Day 2 | 93.28 | 14.15 | |
| Day 3 | 92.14 | 7.18 | |
| Day 1 | 200 | 95.14 | 11.88 | 94.65 | 11.33 |
| Day 2 | 98.98 | 12.68 | |
| Day 3 | 89.84 | 9.45 | |

https://doi.org/10.1371/journal.pone.0217573.t001

| Table 2. The matrix effect quantitative values of gemifloxacin in dialysates (n = 6). |
| Nominal concentration (ng/mL) | Matrix effect (%) |
| | Mean (%) | RSD (%) |
| 4 | 102.16 | 7.56 |
| 40 | 91.32 | 8.39 |
| 200 | 99.36 | 7.45 |

https://doi.org/10.1371/journal.pone.0217573.t002
mg/kg produced an approximate $2 \log_{10}$ CFU/thigh reduction at 24 h after treatment compared with that before treatment.

**Pharmacokinetic and tissue penetration study of gemifloxacin**

To investigate the penetration ability of gemifloxacin into skeletal muscle, free gemifloxacin concentration was determined in skeletal muscle and plasma by MD combined with LC-MS/MS after an 18 mg/kg i.v. bolus dose.

The profiles of free gemifloxacin from 0 to 9 h in plasma and skeletal muscle in both infected and healthy rats are shown in Fig 5. The MIC of gemifloxacin for ATCC 43300 conducted by broth microdilution in cation-adjusted Muller-Hinton broth according to the Clinical and Laboratory Standards Institute (CLSI) protocol [20] was 0.03 mg/L. Free gemifloxacin concentrations were above the MIC during the 9-h sampling period in plasma and muscle as shown in Fig 5. The concentrations of last sampling point ($C_{9\text{h,plasma}}$ and $C_{9\text{h,muscle}}$) were more than 2 folds of MIC. The rapid distribution of gemifloxacin from plasma to muscle and markedly lower free levels of gemifloxacin in skeletal muscle than in plasma were observed. The main PK parameters are summarized and presented in Table 4.

### Table 3. Stability data for gemifloxacin (n = 6).

| Nominal concentration (ng/mL) | %Theoretical 12 h ambient | 2 week frozen (−80˚C) | 3 freeze / thaw cycle | 24 h in autosampler (4˚C) |
|-----------------------------|---------------------------|-----------------------|----------------------|-------------------------|
| 4                           | 94.48±8.69                | 102.16±7.56           | 97.87±4.32           | 96.40±1.75              |
| 40                          | 100.17±1.53               | 91.32±8.39            | 101.45±7.38          | 92.42±3.41              |
| 200                         | 97.40±4.04                | 99.36±7.45            | 91.67±3.32           | 95.98±5.25              |

https://doi.org/10.1371/journal.pone.0217573.t003

![Fig 4. The bacterial density in the thigh infection model (Mean±S.D., n = 4).](https://doi.org/10.1371/journal.pone.0217573.g004)
The corresponding PK parameters for plasma calculated using the noncompartmental model were as follows: $T_{1/2} = 2.12 \pm 0.24 \text{ h}$, $\text{AUC}_{0-9} = 7068.32 \pm 1964.19 \text{ ng h/mL}$, $\text{AUC}_{0-\infty} = 7542.42 \pm 2153.95 \text{ ng h/mL}$ and $C_{\text{max}} = 4726.20 \pm 729.82 \text{ ng/mL}$ in MRSA-infected rats; and $T_{1/2} = 1.33 \pm 0.43 \text{ h}$, $\text{AUC}_{0-9} = 6927.49 \pm 1714.86 \text{ ng h/mL}$, $\text{AUC}_{0-\infty} = 7076.15 \pm 1674.23 \text{ ng h/mL}$ and $C_{\text{max}} = 5027.43 \pm 746.97 \text{ ng/mL}$ in healthy rats. The above parameters were in accordance with the reported data taking into account the protein binding rate [21–22].

Compared with the results for plasma, the results for skeletal muscle revealed a significantly lower $\text{AUC}_{0-9}$ and $C_{\text{max}} (P < 0.05)$ in both healthy (AUC$_{0-9}$ = 3774.72 ± 700.36 ng h/mL and $C_{\text{max}} = 1766.37 \pm 541.64 \text{ ng/mL}$) and infected rats (AUC$_{0-9}$ = 3641.50 ± 915.65 ng h/mL and $C_{\text{max}} = 1675.19 \pm 584.57 \text{ ng/mL}$). The tissue penetration factor (expressed as the mean ratio of the AUC$_{0-9}$ for muscle to the AUC$_{0-9}$ for plasma) for infected rats and healthy rats was 0.52 and 0.54, respectively.

The difference in tissue exposure of gemifloxacin between healthy and MRSA-infected rats was also investigated and analyzed. No significant difference was observed ($P > 0.05$) between healthy and MRSA-infected rats in plasma or thigh muscle.

**Tissue distribution**

The tissue distribution study was performed on infected rats. The concentrations of gemifloxacin in homogenized muscle ($C_m$) are presented in Table 5. To elucidate the distribution of gemifloxacin between the interstitial space and tissue cells, the intracellular concentration

![Fig 5. Free gemifloxacin concentrations in plasma and skeletal muscle after i.v. administration of 18 mg/kg to infected rats (Mean ± S.D., n = 6) and healthy rats (Mean ± S.D., n = 6). The final phase scale is expanded in the inset.](https://doi.org/10.1371/journal.pone.0217573.g005)

**Table 4. Pharmacokinetic parameters$^a$ of gemifloxacin in plasma and skeletal muscle following an intravenous dose of 18 mg/kg (n = 6).**

| Compartiment   | $\text{AUC}_{0-9}$ (h'ng/mL) | $\text{AUC}_{0-\infty}$ (h'ng/mL) | $T_{1/2}$ (h) | $T_{\text{max}}$ (h) | $C_{\text{max}}$ (ng/mL) | $Vd$ (mL/kg) | $\text{CL}$ (mL/h/kg) |
|----------------|-----------------------------|-----------------------------------|--------------|----------------------|--------------------------|-------------|----------------------|
| Plasma (infected rats) | 7068.32±1964.19 | 7542.42±2153.95 | 2.12±0.24 | 0.17±0.00 | 4726.20±729.82 | 7964.85±3127.27 | 2560.83±775.17 |
| Muscle (infected rats) | 3641.50±915.65 | 3920.44±1010.14 | 2.10±0.50 | 0.37±0.30 | 1675.19±584.57 | ND$^b$ | ND$^b$ |
| Plasma (healthy rats) | 6927.49±1714.86 | 7076.15±1674.23 | 1.33±0.43 | 0.17±0.00 | 5027.43±746.97 | 5234.53±2472.32 | 2630±547.64 |
| Muscle (healthy rats) | 3774.72±700.36 | 3962.03±752.62 | 1.87±0.46 | 0.17±0.00 | 1766.37±541.64 | ND$^b$ | ND$^b$ |

$^a$Abbreviations: $\text{AUC}_{0-9}$ area under curve from time zero to 9h; $\text{AUC}_{0-\infty}$ area under curve from time zero to infinity; $T_{1/2}$, the plasma elimination half-life; $T_{\text{max}}$ the time to maximum concentration; $C_{\text{max}}$ the maximum concentration; $Vd$, volume of distribution; $\text{CL}$, Clearance.

$^b$ND, not determined.

[https://doi.org/10.1371/journal.pone.0217573.t004](https://doi.org/10.1371/journal.pone.0217573.t004)
(C_{intra}) and the concentration in the muscle interstitial fluid (C_{isf}, total amount of unbound and bound concentrations) were calculated by the following equations reported by Araki and shown in Table 5 [23].

\[
C_{intra} = \frac{(C_m - C_{isf} \times 0.119)}{0.881} \tag{3}
\]

\[
C_{isf} = C_{isf,u} + C_{isf,b} = C_{isf,u} + C_{pb} \times 0.6 \tag{4}
\]

C_{isfu} is the unbound concentration in interstitial fluid obtained by MD, C_{isfb} is the bound concentration in interstitial fluid, and C_{pb} is the bound concentration in plasma.

The constants of 0.119 and 0.881 were the reported ratios for the interstitial and intracellular volumes, respectively, in rat muscle. A constant of 0.6 was the reported albumin ratio of interstitial fluid to plasma.

As shown in Table 5, the C_{m} obtained using the homogenized tissue, at a comparable level of C_{intra}, was higher than C_{isf}. The result indicated that gemifloxacin is mainly distributed in tissue cells rather than the interstitial space.

### Discussion

Most PK studies on antimicrobial agents are based on the measurement of total plasma concentration. However, antibacterial activity can be exerted only by the drugs of the unbound fraction in the interstitial fluid where the infections occur. In local infection, PK profiles for plasma and target tissues may be markedly different. Therefore, the prediction of antimicrobial efficacy based on plasma PK data may result in overestimation of the dose regimen and failure of antibiotic therapy. Regulatory authorities such as the FDA and European Agency for the Evaluation of Medicinal Products advocate that the concentrations of antibacterial at the target site should be determined.

Islinger et al. found that free gemifloxacin concentrations in muscle were persistently higher than those in plasma over the 10-h study period in healthy volunteers with a penetration factor of 1.7, which was different from the PK characteristics of other fluoroquinolones [24–25].

In the present study, MD combined with LC-MS/MS was applied to determine free gemifloxacin in plasma and skeletal muscle simultaneously in rats. MD is a minimally invasive technique to achieve unbound drug sampling in the tissue of interest and was applied to the tissue distribution investigation in this study. Because of the high purity of the dialysate, sample extraction and the corresponding validation were not required for MD samples. Instead of extraction recovery, the relative recoveries of MD probes were evaluated. There was no significant difference among the three different drug concentrations, which showed that probe
recovery was independent of the concentrations investigated. No significant difference in recoveries was found between the EE and RD methods, indicating that the RD method can be employed for the assessment of in vivo recoveries. Therefore, the in vivo recovery values obtained by the RD method were employed to back calculate the real gemifloxacin concentrations in rat plasma and skeletal muscle.

The concentration-time curve in our study indicated that free gemifloxacin concentrations were above MIC during the 9-h sampling period in both plasma and muscle, which is promising for the treatment of MRSA infections.

A key finding of our study is the significantly lower exposure of gemifloxacin in skeletal muscle than in plasma for both healthy and MRSA-infected rats with penetration factors less than 0.6. This finding represented a completely different profile than the results reported by Islinger et al. [10]. The infection status may cause corresponding pathological and physiological changes and result in altered tissue penetration [26]. Moreover, membrane transport processes such as influx and efflux play a key role in the tissue distribution of antibacterials, and the expression and activity of P-glycoprotein, a membrane transporter, can be altered by the influence of infection and inflammation [27]. Therefore, we speculated that the tissue uptake of gemifloxacin, as a P-glycoprotein substrate [28], may also be affected by the infection status. To investigate the influence of infection status on the tissue penetration of gemifloxacin, both healthy and infected rats were included in the experimental design. However, our results proved that there was no significant difference in gemifloxacin exposure between healthy and MRSA-infected rats in plasma or thigh muscle. Our findings also proved that infected rats can be replaced by healthy rats in the PK/PD studies of gemifloxacin in rats, which will be highly convenient for in vivo PK/PD studies.

Several other reasons can account for this difference. First, the species difference between rats and humans may lead to different tissue distributions of gemifloxacin. This finding also suggested that the extrapolation of PK/PD data from rats to humans should be approached with caution. The sampling method may be another factor that affected the final results. Different methods were employed for the determination of free gemifloxacin in plasma in our study and Islinger's study. The free concentrations in plasma calculated based on the total drug concentration determined by protein precipitation extraction and the plasma protein binding rate may be less accurate than those achieved directly by MD.

Similar to other fluoroquinolones, gemifloxacin is a concentration-dependent antibacterial, and the ratio of AUC\textsubscript{0-24} to the MIC\textsubscript{90} is the most relevant PK/PD parameter to clinical efficacy [29–30]. The relatively low AUC of gemifloxacin in skeletal muscle compared with that in plasma indicated that the dosing regimen according to drug levels in plasma for the treatment of local tissue infections is unreasonable and might result in insufficient dosage or even drug resistance. Therefore, it is important to precisely determine the free drug levels in target tissues to confirm the antimicrobial efficacy.

The present study also measured and compared the concentrations of gemifloxacin from homogenized tissue and interstitial fluid in infected rats. Tissue homogenization is the traditional method for tissue distribution studies. However, bacterial infections are usually restricted to extravascular interstitial spaces, and only the unbound fraction exhibits antimicrobial effects. Therefore, it is important to evaluate the distribution in tissue interstitial space and intracellular space separately, especially the unbound concentrations in tissue interstitial fluid, for an antimicrobial agent. The result of $C_{\text{intra}}\approx C_m > C_{\text{isf}}$ for gemifloxacin, consistent with the previously reported result of ciprofloxacin [23], further demonstrated that compared with the muscle concentration from tissue homogenization, the unbound concentration of gemifloxacin in tissue interstitial fluid measured using MD is extremely valuable for the evaluation of antimicrobial effects.
The present work is the first to investigate the penetration ability of free gemifloxacin in infected skeletal muscle in rats. A rodent model for the PK/PD study of gemifloxacin in local infection was also established.

Conclusions

In conclusion, this validated method was successfully applied to quantify free gemifloxacin concentrations in rat plasma and thigh muscle and provides the possibility to investigate the real concentrations of gemifloxacin in different parts of the body simultaneously, which would shed light on the dosing regimen optimization of gemifloxacin. The significantly lower free gemifloxacin concentrations in skeletal muscle than in plasma in MRSA-infected rats suggested that the dosing regimen according to drug levels in plasma to the treatment of local tissue infection is unreasonable.

Author Contributions

Conceptualization: Jian-Dong Jiang, Jing Pang, Xue-Fu You.

Data curation: Xin-Yi Yang, Xiukun Wang.

Investigation: Rui Zhao, Qing Wang, Xin-Xin Hu, Tong-Ying Nie.

Writing – original draft: Rui Zhao.

Writing – review & editing: Cong-Ran Li, Xi Lu, Jing Pang.

References

1. A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation, Turk J Pharm Sci. 2019; 16(1):8–13.

2. Marino A, Blanco AR, Ginestra G, Nostro A, Bisignano G. Ex vivo efficacy of gemifloxacin in experimental keratitis induced by methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob Agents. 2016; 48: 395–400. https://doi.org/10.1016/j.ijantimicag.2016.06.026 PMID:27554440

3. Azeredo FJ, Dalla Costa T, Derendorf H. Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions. Clin Pharmacokinet. 2014; 53: 205–212. https://doi.org/10.1007/s40262-014-0131-8 PMID:24452811

4. Roberts JA, Norris R, Paterson D, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012; 73: 27–36. https://doi.org/10.1111/j.1365-2125.2011.04080.x PMID:21831196

5. Ambrose PG. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2006; 26: 129–134. PMID:16506954

6. Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2004; 48: 4246–4249. https://doi.org/10.1128/AAC.48.5.4246-4249.2004 PMID:15105091

7. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, et al. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol. 2007; 47: 589–603. https://doi.org/10.1177/0091270006299091 PMID:17442695

8. Muller M, De La Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004; 48: 1441–1453. https://doi.org/10.1128/AAC.48.5.1441-1453.2004 PMID:15105091

9. Saravolatz LD, Leggott J, Gatilfoxcin, gemifloxacin and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis. 2003; 37: 1210–1215. https://doi.org/10.1086/378809 PMID:14557966

10. Islinger F, Bouw R, Stahl M, Lackner E, Zeleny P, Brunner M, et al. Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. Antimicrob Agents Chemother. 2004; 48: 4246–4249. https://doi.org/10.1128/AAC.48.11.4246-4249.2004 PMID:15504648
11. Nix DE, Matthias KR, Ferguson EC. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother. 2004; 48: 3419–3424. https://doi.org/10.1128/AAC.48.9.3419-3424.2004 PMID: 15328106

12. Hutschal a D, Kinstner C, Skhirladze K, Mayer-Helm BX, Zeitlinger M, Wisser W, et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. Intensive Care Med. 2008; 34: 1827–1834. https://doi.org/10.1007/s00134-008-1122-8 PMID: 18478200

13. Bush K, Macielag M. New approaches in the treatment of bacterial infections. Curr Opin Chem Biol. 2000, 4: 433–439. PMID: 10959772

14. Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation (2013). US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine.

15. Tasso L, Bettoni CC, Oliveira JK, Dalla Costa T. Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats. Int J Pharm. 2008; 358: 96–101. https://doi.org/10.1016/j.ijpharm.2008.02.023 PMID: 18400426

16. de Araújo BV, Laureano JV, Grünspan LD, Dalla Costa T, Tasso L. Validation of an efficient LC-microdialysis method for gemifloxacin quantitation in lung, kidney and liver of rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 919–920: 62–66.

17. Fulzele SV, Babu RJ, Aghanou E, Singh M. Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology. 2007; 237: 77–88. https://doi.org/10.1016/j.tox.2007.05.005 PMID: 17574719

18. Carvalho JF, Azevedo IM, Rocha KB, Carriço AD. Oxacillin magnetically targeted for the treatment of Methicillin-Resistant S. aureus infection in rats. Acta Cir Bras. 2017; 32(1); 46–55. https://doi.org/10.1590/s0102-865020170106 PMID: 28225917

19. Banevericius MA, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother. 2013; 25(1): 26–31. https://doi.org/10.1179/1973947812Y.0000000061 PMID: 23433441

20. Clinical and Laboratory Standards Institute. 2013. Wayne, PA. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically—11th edition. Approved standard M07-A10. 2012; 27–30

21. Ramji JV, Austin NE, Boyle GW, Chalker MH, Duncan G, Fairless AJ, et al. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs. Drug Metab Dispos. 2001; 29: 435–442. PMID: 11259328

22. Kaiser M, Grünspan LD, Costa TD, Tasso L. Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 3639–3644. https://doi.org/10.1016/j.chromb.2011.09.011 PMID: 21963480

23. Araki H, Ogake N, Tsuneda R, Minami S, Watanabe Y, Tamai I, et al. Muscle distribution of antimicrobial agents after a single intravenous administration to rats. Drug Metab Pharmacokinet. 2002; 17(3): 237–44. PMID: 15618675

24. Brunner M, Hollenstein U, Delacher S, Jaeger D, Schmid R, Lackner E, et al. Antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob Agents Chemother. 1999; 43: 2345–2349. PMID: 10508004

25. Bernardi PM, Barreto F, Dalla Costa T. Application of a LC-MS/MS method for evaluating lung penetration of tobramycin in rats by microdialysis. J Pharm Biome Anal. 2017; 134: 3639–3644. https://doi.org/10.1016/j.jpba.2011.09.011 PMID: 21999341

26. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008; 4: 1245–1264. https://doi.org/10.1517/17425255.4.10.1245 PMID: 18798696

27. Jinh HE, Song B, Kim SB, Shim WS, Kim DD, Chong S, Chung SJ, Shim CK. Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug. Xenobiotica. 2013; 43: 355–67. https://doi.org/10.3109/00498254.2012.720740 PMID: 23020787

28. Labreche MJ, Frei CR. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. Am J Health Syst Pharm. 2012; 69: 1863–1870. https://doi.org/10.2146/ajhp110464 PMID: 23116760

29. Segreti J, Jones RN, Bertino JS Jr. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther. 2012; 28: 3–11. https://doi.org/10.1089/jop.2011.0072 PMID: 21999341